1st Department of Medicine Semmelweis University
Academic coordinator for the English medical programme:
Peter Studinger MD.
Administrator for the English medical programme
Our Institute started to operate as the 2nd Department of Internal Medicine of the Semmelweis University in 1909, led by Ernő Jendrassik. From 1921 the hospital was reconstituted as the 3rd Department of Internal Medicine in the current building headed by the Baron Sándor Korányi, who previously led the 3rd Department of Internal Medicine in the building currently hosting the Semmelweis University Department of Urology between 1909 and 1921. Baron Sándor Korányi was a preeminent scientist – creating the definition of renal failure – while also being an excellent internist and a legendary lecturer. His greatest body of work was however was his role in creating a school of medicine that made him the greatest Hungarian internist of the entire 20th century.
From 1936 Ferenc Herczog ensued as head of the institute then renamed as 1st Department of Internal Medicine. The Department was led by István Rusznyák between 1946 to 1963, then by István Holló as interim head from 1963 to 1965, then by Imre Magyar from 1965 to 1981, then by István Holló from 1981 to 1993, followed by Rudolf de Châtel from 1993 to 2003 and finally by Csaba Farsang between 2003 and 2007. Current Head of Department is Miklós Szathmári from April 2007.
The principles of the Korányi school, namely optimistic humanism, the demand and respect for scientific knowledge and the representation of integrative, universal internal medicine has been a continuous hallmark of the Department, although with a constantly changing emphasis between these aims. This philosophy is indicated by the fact that the Department is occasionally referred to as ’Korányi Clinic’ even today.
The teaching, healthcare and scientific activities of the Department developed in a tight unison. The teaching represents the full spectrum of healthcare training, including the treatment of medical and nursing students and also the specialization in internal medicine and its subspecialties. An entire class of medical students is trained in internal medicine for three-and-a-half years in the Department. The institute also partakes in the internal medicine training of other specialties and that of the pharmacist students. The hospital operates on 102 inpatients beds while also having 8 day-care beds for hematological malignancies. The healthcare activities representing a broad area of internal medicine are conducted in co-operative working groups led by nationally – and in some cases internationally – recognized experts of the subspecialties.
Lead clinical specialties of the Department are Hematology, Nephrology, Endocrinology - particularly disorders of the calcium homeostasis, treatment of diabetes mellitus and diagnostics and radionuclide treatment for thyroid disease -, Hepatology and Gastroenterology including endoscopic interventions. Treatment of hematological patients is carried out on 17 inpatient beds. There are two rooms suitable for isolation of cytopenic patients. The 19-bed Nephrology-Immunology ward operates in conjunction with the Fresenius Dialysis Centre also operating within the hospital building of the Department. From July 2007 a plasmapheresis center complements the work of the Nephrology-Immunology and Hematology wards. From 2014 photopheresis procedure is also feasible in the therapeutic apheresis center.
Within our Metabolism and Endocrinology profile there is a special emphasis on diabetes care, including the management gestational diabetes and treatment of metabolic emergencies. Radionuclide treatment for thyroid disease and various other disorders is administered on 4 beds in our Isotope Therapeutic Unit. High dose radionuclide ablation of thyroid malignancies is also carried out at this ward. There are state-of-the-art diagnostic options for disorders of calcium homeostasis available; our Department is equipped with a complete diagnostic arsenal for evaluation of bone mineral density and determination of special diagnostic parameters for evaluation of bone metabolism.
Our Clinical Pharmacology Unit has been licensed for the conduction of phase 1 to 4 clinical trials since 2005. Our Gastroenterology Unit has 10 inpatient beds for endoscopic procedures, management of liver disease and preparing patients for receiving liver transplant. The 30-bed general medicine ward was complemented by a 5-bed sub-intensive High Dependency Unit that provides primarily an option for close monitoring of patients with cardiovascular disease.
Outpatient care in the Department operates on multiple outpatient clinics specializing in Nephrology, Hypertension, Hematology, Hemostasis, Metabolism-Endocrinology, Gastroenterology, Cardiology, Apheresis, Bone-densitometry, Isotope Diagnostics and General Medicine with Consultants providing outpatient care a total 318 hours weekly.
The Molecular Biology Laboratory located in the Department operates with diagnostics of viral hepatitis and thrombophilias, and also research for molecular biology of bone disease as primary scientific profile.
• Endothelial Function in Patients With Renal Failure
• Vascular Elasticity in Patients With Chronic Renal Failure
• Renal osteodystrophy
• Quality of Life Measurements in Kidney Transplant Recipients
• Determination of Genetic Predisposing Factors in Patients with Secondary Hypertension
• Genetic Background, Diagnostics, and Management in Disorders of Bone Metabolism
• Relationship Between Vitamin D and Colorectal Neoplasms
• Gestation and Diabetes
• Screening, Management and Follow-up of Gestational Diabetes
• Quality Assurance in DIabetes Care
• Diabetic Neuropathy
• Pathogenesis of Chronic Liver Disease and Complications
• Pathogenesis of Chronic Viral Hepatitis’s and Complications
• Pathogenesis and Current Treatment of Inflammatory Bowel Disease
• Disorders of Hemostasis Accompanying Malignant Hematological Diseases
• Molecular Biological Aspects and Current Treatment of Lymphoproliferative and Myeloproliferative Neoplasms
STUDENT SCIENTIFIC ASSOCIATION (TDK) TOPICS
• Determination of hydration state with special regards to fractionated excretions of sodium, uric acid and carbamide
• Management of patients with primary immune thrombocytopenia and side effects of current treatment modalities
• Rare hematological disorders: role of early discovery in effective treatment
• Cardiovascular and metabolic aspects of chronic myelogenous leukemia (CML)
• Methods for improving patient adherence in the management of chronic myelogenous leukemia: role of patient support groups
• Diagnostics and treatment of Philadelphia negative chronic myeloproliferative neoplasms
• Cardiovascular risk factors in the management of polycythemia vera, essential thrombocythemia and primary myelofibrosis
• Role of PET/CT in the management of diffuse large B-cell lymphoma
• The role of the Hematologist in the diagnostics and treatment of cutaneous lymphomas
• Optimal treatment for MALT lymphomas
• Results of treating hairy cell leukemia in our institution and comparison to international treatment cohorts
• Course of the disease in treated hairy cell leukemia patients
• In vivo pharmacological studies in hematological malignancies
• Prognosis and choice of treatment for inflammatory bowel disease
• Predicting prognosis in inflammatory bowel disease, role of clinical, endoscopic and biomarker predicting factors
• Epidemiology, etiology and prognosis of upper and lower gastrointestinal bleeding
• Pathogenetic factors in the development of differentiated thyroid cancer
• Effects of change in vitamin D metabolism on the cardiovascular system
• Examination of bone mass and frequency of fracture in patients with recidive kidney stones
• Autonomic and sensory neuropathy in patients with impaired glucose tolerance or with elevated risk for diabetes
• Correlation of thin filament neuropathy and diabetic neuropathy in patients with type II diabetes mellitus
• Analysis of characteristic parameters of diabetic neuropathy and cardiovascular parameters discovered in autopsy studies
• Role of cardiovascular risk factors in development of neuropathy in patients with impaired glucose tolerance